Cargando…

2-Year survival benefit from immunotherapy for squamous cell cancer with cancer of unknown primary in mediastinum: a case report

Cancers of unknown primary (CUP) account for 2%–5% of all diagnosed cancers and are always characterized with fast-paced aggression, early metastasis, and unpredictable spread patterns Mediastinum metastasis with unknown primary origin is extremely rare and with a poor prognosis and short survival....

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Wei, Zhao, Nan, Zhang, Manze, Li, Zhihua, Wang, Ning, Shen, Wennan, Dong, Yuemei, Nie, Yanli, Li, Zhaoxia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598860/
https://www.ncbi.nlm.nih.gov/pubmed/37886174
http://dx.doi.org/10.3389/fonc.2023.1242460
_version_ 1785125647856697344
author Zhao, Wei
Zhao, Nan
Zhang, Manze
Li, Zhihua
Wang, Ning
Shen, Wennan
Dong, Yuemei
Nie, Yanli
Li, Zhaoxia
author_facet Zhao, Wei
Zhao, Nan
Zhang, Manze
Li, Zhihua
Wang, Ning
Shen, Wennan
Dong, Yuemei
Nie, Yanli
Li, Zhaoxia
author_sort Zhao, Wei
collection PubMed
description Cancers of unknown primary (CUP) account for 2%–5% of all diagnosed cancers and are always characterized with fast-paced aggression, early metastasis, and unpredictable spread patterns Mediastinum metastasis with unknown primary origin is extremely rare and with a poor prognosis and short survival. There is no literature to refer to for its treatment. Here, we reported a case of squamous cell CUP in the mediastinum. A 50-year-old male patient was admitted after multi-line treatment of low differentiated squamous cell carcinoma in the mediastinum diagnosed 8 months before. In August 2019, the patient went to a local hospital for cough and dyspnea for 2 weeks. Then, he was diagnosed with squamous cell carcinoma of unknown primary origin with multiple lymph nodes metastasis. The patient was featured with programmed cell death-ligand 1 (PD-L1) expression strongly positive in 90% of tumor cells and the combined positive score of 90 and a tumor mutation burden of 1.79 MUts/Mb and microsatellite stable phenotype. The patient was treated with anti-programmed cell death-1 (PD-1) antibodies in combination with chemotherapy and responded to the treatment. The patient showed stable disease to multi-line immunotherapy for more than 7 months and finally got a clinical benefit of 2-year survival benefit. In conclusion, immunotherapy targeting PD-1/PD-L1 in combination with chemotherapy may play a crucial role in the later-line treatment and palliative care of CUP.
format Online
Article
Text
id pubmed-10598860
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-105988602023-10-26 2-Year survival benefit from immunotherapy for squamous cell cancer with cancer of unknown primary in mediastinum: a case report Zhao, Wei Zhao, Nan Zhang, Manze Li, Zhihua Wang, Ning Shen, Wennan Dong, Yuemei Nie, Yanli Li, Zhaoxia Front Oncol Oncology Cancers of unknown primary (CUP) account for 2%–5% of all diagnosed cancers and are always characterized with fast-paced aggression, early metastasis, and unpredictable spread patterns Mediastinum metastasis with unknown primary origin is extremely rare and with a poor prognosis and short survival. There is no literature to refer to for its treatment. Here, we reported a case of squamous cell CUP in the mediastinum. A 50-year-old male patient was admitted after multi-line treatment of low differentiated squamous cell carcinoma in the mediastinum diagnosed 8 months before. In August 2019, the patient went to a local hospital for cough and dyspnea for 2 weeks. Then, he was diagnosed with squamous cell carcinoma of unknown primary origin with multiple lymph nodes metastasis. The patient was featured with programmed cell death-ligand 1 (PD-L1) expression strongly positive in 90% of tumor cells and the combined positive score of 90 and a tumor mutation burden of 1.79 MUts/Mb and microsatellite stable phenotype. The patient was treated with anti-programmed cell death-1 (PD-1) antibodies in combination with chemotherapy and responded to the treatment. The patient showed stable disease to multi-line immunotherapy for more than 7 months and finally got a clinical benefit of 2-year survival benefit. In conclusion, immunotherapy targeting PD-1/PD-L1 in combination with chemotherapy may play a crucial role in the later-line treatment and palliative care of CUP. Frontiers Media S.A. 2023-10-11 /pmc/articles/PMC10598860/ /pubmed/37886174 http://dx.doi.org/10.3389/fonc.2023.1242460 Text en Copyright © 2023 Zhao, Zhao, Zhang, Li, Wang, Shen, Dong, Nie and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Zhao, Wei
Zhao, Nan
Zhang, Manze
Li, Zhihua
Wang, Ning
Shen, Wennan
Dong, Yuemei
Nie, Yanli
Li, Zhaoxia
2-Year survival benefit from immunotherapy for squamous cell cancer with cancer of unknown primary in mediastinum: a case report
title 2-Year survival benefit from immunotherapy for squamous cell cancer with cancer of unknown primary in mediastinum: a case report
title_full 2-Year survival benefit from immunotherapy for squamous cell cancer with cancer of unknown primary in mediastinum: a case report
title_fullStr 2-Year survival benefit from immunotherapy for squamous cell cancer with cancer of unknown primary in mediastinum: a case report
title_full_unstemmed 2-Year survival benefit from immunotherapy for squamous cell cancer with cancer of unknown primary in mediastinum: a case report
title_short 2-Year survival benefit from immunotherapy for squamous cell cancer with cancer of unknown primary in mediastinum: a case report
title_sort 2-year survival benefit from immunotherapy for squamous cell cancer with cancer of unknown primary in mediastinum: a case report
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598860/
https://www.ncbi.nlm.nih.gov/pubmed/37886174
http://dx.doi.org/10.3389/fonc.2023.1242460
work_keys_str_mv AT zhaowei 2yearsurvivalbenefitfromimmunotherapyforsquamouscellcancerwithcancerofunknownprimaryinmediastinumacasereport
AT zhaonan 2yearsurvivalbenefitfromimmunotherapyforsquamouscellcancerwithcancerofunknownprimaryinmediastinumacasereport
AT zhangmanze 2yearsurvivalbenefitfromimmunotherapyforsquamouscellcancerwithcancerofunknownprimaryinmediastinumacasereport
AT lizhihua 2yearsurvivalbenefitfromimmunotherapyforsquamouscellcancerwithcancerofunknownprimaryinmediastinumacasereport
AT wangning 2yearsurvivalbenefitfromimmunotherapyforsquamouscellcancerwithcancerofunknownprimaryinmediastinumacasereport
AT shenwennan 2yearsurvivalbenefitfromimmunotherapyforsquamouscellcancerwithcancerofunknownprimaryinmediastinumacasereport
AT dongyuemei 2yearsurvivalbenefitfromimmunotherapyforsquamouscellcancerwithcancerofunknownprimaryinmediastinumacasereport
AT nieyanli 2yearsurvivalbenefitfromimmunotherapyforsquamouscellcancerwithcancerofunknownprimaryinmediastinumacasereport
AT lizhaoxia 2yearsurvivalbenefitfromimmunotherapyforsquamouscellcancerwithcancerofunknownprimaryinmediastinumacasereport